



Astec LifeSciences Ltd.

Date: 24th June, 2022

To,
BSE Limited
P. J. Towers, Dalal Street, Fort,
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: BSE Scrip Code No. “533138”

Ref: “ASTEC”

Dear Sir / Madam,

Sub.: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Credit Rating from ICRA Limited for Rs. 839 Crore Bank Facilities of Astec LifeSciences Limited

Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the SEBI Regulations”), this is to inform you that we are in receipt of intimation letter from ICRA Limited (“ICRA”) dated 23rd June, 2022, re-affirming / assigning the long-term rating of “[ICRA]AA-” (pronounced ‘ICRA double A minus’) and the short term rating of “[ICRA]A1+” (pronounced ‘ICRA A one plus’) for the Rs. 839 Crore (enhanced from Rs.574 Crore) Fund Based and Non-Fund Based facilities of the Company. Further, ICRA has revised the outlook on the long-term rating from ‘Stable’ to ‘Positive’.

Further, pursuant to Regulation 30(8) of the SEBI Regulations, this intimation will also made available on the Company’s website at www.astecls.com

Kindly take the above on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai-400079,
Maharashtra, India
Telephone No.: 022- 25188010
Fax No.: 022-22618289
Email id: astecinfo@godrejastec.com
Website: www.astecls.com
CIN : L99999MH1994PLC076236